Synthesis, cytotoxicity, and structure-activity relationship (SAR) studies of andrographolide analogues as anti-cancer agent

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 23, 2010, Pages 6947-6950

  Das, Bimolendu ^a   Chowdhury, Chinmay ^a   Kumar, Deepak ^a   Sen, Rupashree ^b   Roy, Rajneeta ^a   Das, Padma ^a   Chatterjee, Mitali ^b  

^a INDIAN INSTITUTE OF CHEMICAL BIOLOGY   (India)

^b INSTITUTE OF POST GRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Analogue; Andrographolide; Anti cancer; Apoptosis; C14 ester

Indexed keywords

ALKYL GROUP; ANDROGRAPHOLIDE; ANTINEOPLASTIC AGENT; GAMMA BUTYROLACTONE DERIVATIVE; HYDROXYL GROUP;

ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IN VITRO STUDY; INFRARED SPECTROSCOPY; MASS SPECTROMETRY; NUCLEAR MAGNETIC RESONANCE; QUANTUM YIELD; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION;

4-BUTYROLACTONE; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DITERPENES; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; LEUKEMIA; MOLECULAR STRUCTURE; SPECTRUM ANALYSIS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 78149280792     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.09.126     Document Type: Article

References (38)

1. S. Bonazzi, O. Eidam, S. Guttinger, J.-Y. Watch, I. Zemp, U. Kutay, and K. Gademann J. Am. Chem. Soc. 132 2010 1432
2. D.J. Newman, and G.M. Cragg J. Nat. Prod. 70 2007 461
3. D.J. Newman, G.M. Cragg, and K.M. Snader J. Nat. Prod. 66 2003 1022
4. R. Husen, A.H.L. Pihie, and M. Nallappan J. Ethnopharmacol. 95 2004 205
5. P. Misra, N.L. Pal, P.Y. Guru, J.C. Katiyar, V. Srivastava, and J.S. Tandon Int. J. Pharmacognosy 30 1992 263
6. S. Gupta, M.A. Choudhry, J.N.S. Yadava, V. Srivastava, and J.S. Tandon Pharm. Biol. 28 1990 273
7. S. Madav, S.K. Tanda, J. Lal, and H.C. Tripathi Fitoterapia 67 1996 452
8. B. Saraswat, P.K. Visen, G.K. Patnaik, and B.N. Dhawan Fitoterapia 66 1995 415
9. H.Y. Zhao, and W.Y. Fang Chin. Med. J. 104 1991 770
10. A. Puri, R. Saxena, R.P. Saxena, K.C. Saxena, V. Srivastava, and J.S. Tandon J. Nat. Prod. 56 1993 995
11. K.R. Kirtikar, and B.D. Basu Indian Medicinal Plants Vol. 3 1975 Periodical Experts New Delhi 1884
12. S. Rajagopal, R.A. Kumar, D.S. Deevi, C. Satyanarayana, and R. Rajagopalan J. Exp. Ther. Oncol. 3 2003 147
13. C.-G. Jiang, J.-B. Li, F.-R. Liu, T. Wu, M. Yu, and H.-M. Xu Anticancer Res. 27 2007 2439
14. M. Geethangili, Y.K. Rao, S.-H. Fang, and Y.-M. Tzeng Phytother. Res. 22 2008 1336
15. L. Yang, D. Wu, K. Luo, S. Wu, and P. Wu Cancer Lett. 276 2009 180
16. J. Li, H.-Y. Cheung, Z. Zhang, G.K.L. Chan, and W.-F. Fong Eur. J. Pharmacol. 568 2007 31
17. S. Nanduri, V.K. Nyavanandi, S.S.R. Thunuguntla, S. Kasu, M.K. Pallerla, P.S. Ram, S. Rajagopal, R.A. Kumar, R. Ramanujam, J.M. Babu, K. Vyas, A.S. Devi, G.O. Reddy, and V. Akella Bioorg. Med. Chem. Lett. 14 2004 4711
18. S.R. Jada, C. Matthews, M.S. Saad, A.S. Hamzah, N.H. Lajis, M.F.G. Stevens, and J. Stanslas Br. J. Pharmacol. 155 2008 641
19. S.R. Jada, G.S. Subur, C. Matthews, A.S. Hamzah, N.H. Lajis, M.S. Saad, M.F.G. Stevens, and J. Stanslas Phytochemistry 68 2007 904
20. C. Satyanarayana, D.S. Deevi, R. Rajagopalan, N. Srinivas, and S. Rajagopal BMC Cancer 4 2004 26 article no. 26.
21. H.-W. Xu, J. Zhang, H.-M. Liu, and J.-F. Wang Synth. Commun. 36 2006 407
22. V. Srivastava, M.P. Darokar, A. Fatima, J.K. Kumar, C. Chowdhury, H.O. Saxsena, G.R. Dwivedi, K. Shrivastava, V. Gupta, S.K. Chattopadhyay, S. Luqman, M.M. Gupta, A.S. Negi, and S.P.S. Khanuja Bioorg. Med. Chem. 15 2007 518
23. T.-H. Chao, T. Lam, B.G. Vong, P.G. Traves, S. Hortelano, C. Chowdhury, F.R. Bahjat, G.K. Lloyd, L.L. Moldawer, L. Bosca, M.A. Palladino, and E.A. Theodorakis ChemBiochem 6 2005 133
24. M. Deshmukh, P. Chao, H.L. Kutscher, D. Gao, and P.J. Sinko J. Med. Chem. 53 2010 1038
25. Z. Wu, A. Patel, R. Dave, and X. Yuan Bioorg. Med. Chem. Lett. 20 2010 3851
26. B. Schmid, D.-E. Chung, A. Warnecke, I. Fichtner, and F. Kratz Bioconjugate Chem. 18 2007 702
27. J.-R. Dai, Y.F. Hallock, J.H. Cardellina II, and M.R. Boyd J. Nat. Prod. 62 1999 1427
28. G.-F. Dai, H.-W. Xu, J.-F. Wang, F.-W. Liu, and H.-M. Liu Bioorg. Med. Chem. Lett. 16 2006 2710
29. R = 6.8, 8.9, 16.9, 17.2, 17.8 and 18.4 min (for compounds 6a, 6b, 9a, 9b, 13a and 13b, respectively).
30. All the synthesized final analogues were generally preserved at 0 to -4 °C and remained stable for months. Even allowing them to stand at rt for several weeks did not lead to any decomposition (HPLC analysis). Besides, few of the final analogues (6a, 9a, 11a-b, 13a) were found to be soluble in chloroform but all of them were fairly soluble in methanol and dimethyl sulfoxide (DMSO) as well.
31. 8: C, 63.98; H, 7.61. Found: C, 64.02; H, 7.56.
32. S. Ganguly, S. Bandyopadhyay, A. Sarkar, and M. Chatterjee J. Microbiol. Methods 66 2006 79
33. 50 values, that is, the concentration that inhibited 50% of cell growth, enumerated by graphic extrapolation using Graph pad prism software (version 5).
34. N.G. Kundu, and S.K. Dasgupta J. Chem. Soc., Perkin Trans 1 1993 2657
35. J.S. Finer-Moore, W.R. Montfort, and R.M. Stroud Biochemistry 29 1990 6977
36. L.W. Hardy, J.S. Finer-Moore, W.R. Montfort, M.O. Jones, D.V. Santi, and R.M. Stroud Science 235 1987 448
37. 2, pH 7.4). Annexin V-FITC and propidium iodide were then added according to the manufacturer's instructions and incubated for 15 min in the dark at 25 °C. Data was acquired using a FACS Calibur flow cytometer and analyzed with Cell Quest Pro software.
38. 50 concentration (5.47 μM) of 6a (for 24 h), washed with ice cold PBS and stained with Hoechst 33258 (10 μg/ml, 30 min). The cells were mounted on poly l-lysine coated slides and analyzed in a laser scanning confocal microscope (Leica TCS SP2 system, Leica microsystem, Heidelberg, Germany; 100×). At least 20 microscopic fields were observed for each sample.